BEQOM
12.9.2019 15:02:08 CEST | Business Wire | Press release
beqom, a cloud-based compensation software provider, today announced that it has partnered with NGA Human Resources, a leading provider of digital HR and multi-country payroll services, to provide enterprise clients with a single best in class platform for managing Total Reward and compensation programs.
beqom’s platform is ideally suited to organizations that can’t compromise when it comes to maximizing their employee performance in line with their business strategy, by rewarding their employees to drive their satisfaction and trust, retain their talents and comply with security and pay equity requirements.
With immediate effect, NGA HR’s consultancy and delivery teams will integrate beqom’s Total Compensation Management Cloud Solution into existing and new cloud HR infrastructures to create a single platform for managing HR and sales compensation uniformly across all operating countries.
Data from all HR, workforce management and sales platforms is captured within the platform. The data can then be analyzed, cut and presented to provide real-time, retrospective or forward-looking analytics and planning. This single situational view will bring multiple benefits to NGA HR’s clients and their employees.
For the business, it makes it easy to understand the performance and retention returns on specific rewards and incentive programs. Budgets can be set against projected impact intelligence and what-if scenarios can simulate the potential of proposed rewards programs, for example, per employee population for country.
For employees, it presents the total value of rewards – addressing the compensation gap that sees many employees leaving organizations for perceived higher salaries. It also makes it very easy for employees to see what they need to achieve for financial reward. This can be a huge motivator and drive the efficiency of individuals and business groups.
For HR and rewards teams, the efficiency and performance gains are manifold. The platform addresses the challenges of managing multiple currencies, languages, time zones and rewards cultures across the business. It supports the local governance of global policies, and workflows ensure that all employees are rewarded fairly, compliantly and on time.
“beqom’s, Total Compensation Management Cloud Solution complements well our portfolio of HR technology and analytics solutions. Many of our clients already have the platform connecting some or all their country locations. For these, we can easily integrate the management of the platform into existing services,” explained Simon Porter, VP Digital HR at NGA Human Resources.
“For organizations looking to create visibility into rewards and compensation programs, we can build the platform into existing and new cloud HR infrastructures to provide the analytics, reporting, modeling and simulation capabilities enterprises need to maximize performance, increase retention, streamline costs and ensure compliance,” continued Simon Porter, VP Digital HR at NGA Human Resources.
"NGA HR has been successfully deploying HR technologies and running core HR processes for multi-national clients for many years. Knowing their clients’ needs for a reliable unified Total Rewards Management solution, NGA selected beqom as a key element of its HR services portfolio,” explained François D’Haegeleer, Global Head of Business Development at beqom.
About beqom
Happiness is the best driver for success.
Our mission is to make the workforce of our customers happy. beqom drives happiness by allowing business managers to lead, align, and motivate employees and partners. beqom’s cloud-based total compensation platform is used globally across all industry sectors by over 100 large companies such as Microsoft and Vodafone. It addresses all performance and compensation aspects such as salary review, bonus, long-term incentives, commissions, benefits, non-cash rewards and all key drivers towards Employee Performance Management and Sales Performance Management. HR, sales, and finance leverage our platform to drive performance, retention, cost optimization, efficiency, compliance and… happiness among their people.
About NGA Human Resources
At NGA HR, our mission is to innovate HR & Payroll for today and tomorrow. We help our clients deliver seamless workforce and payroll services and empower HR as strategic partner for data-driven workforce decisions. As a result, HR leaders can offer better employee experiences, more easily attract and retain talent, manage the employee life cycle and support the globally connected, agile workforce.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190912005322/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
